Abstract
The treatment of epidermal growth factor receptor (EGFR)-driven non-small cell lung cancers with the T790M resistance mutation remains a significant unmet medical need. We report the identification of 4-aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of EGFR, with excellent activity against the T790M resistance double mutants and initial single activating mutants. Using an optimization strategy focused on structure-based design and improving PK properties through metabolite identification, we obtained advanced leads with high oral exposure.
Keywords:
Dihydrofuropyrimidine; EGFR inhibitor; Epidermal growth factor receptor; Non-covalent.
Copyright © 2015 Elsevier Ltd. All rights reserved.
MeSH terms
-
Acrylamides / pharmacology
-
Aniline Compounds / pharmacology
-
Animals
-
Binding Sites
-
Crystallography, X-Ray
-
Dogs
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / chemistry
-
Erlotinib Hydrochloride / pharmacology
-
Furans / chemical synthesis
-
Furans / chemistry
-
Furans / pharmacokinetics
-
Furans / pharmacology*
-
Hepatocytes / metabolism
-
High-Throughput Screening Assays
-
Humans
-
Hydrogen Bonding
-
Indazoles / chemical synthesis
-
Indazoles / chemistry
-
Indazoles / pharmacokinetics
-
Indazoles / pharmacology*
-
Mice
-
Microsomes, Liver / metabolism
-
Point Mutation
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacokinetics
-
Protein Kinase Inhibitors / pharmacology*
-
Pyrimidines / chemical synthesis
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacokinetics
-
Pyrimidines / pharmacology*
-
Rats
Substances
-
Acrylamides
-
Aniline Compounds
-
Furans
-
Indazoles
-
Protein Kinase Inhibitors
-
Pyrimidines
-
osimertinib
-
Erlotinib Hydrochloride
-
ErbB Receptors